

From: [Gildner, Jean](#)  
To: [Janice Castillo \(jcastillo@Portola.com\)](mailto:Janice.Castillo@Portola.com)  
Subject: BLA125586 Portola Label  
Date: Tuesday, May 01, 2018 6:16:29 PM  
Attachments: [3 BLA 125586 FDAv6-20180420-PTLA-response3 20180501.docx](#)  
[image001.png](#)

---

Dear Janice,

Please see attached the final label. There are 3 comments for you. Please revise and send back via email and as an amendment as soon as possible.

Please confirm receipt of this email.

Sincerely, Jean

*Jean F. Gildner* MSHS, MT (ASCP)

**Regulatory Project Manager**  
**Center for Biologics Evaluation and Research**  
**Office of Tissues and Advanced Therapies**  
**U.S. Food and Drug Administration**

Tel: 240-402-8296

[jean.gildner@fda.hhs.gov](mailto:jean.gildner@fda.hhs.gov)



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.